• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Selpercatinib showed promising clinical activity in tumour-agnostic patients with RET­ fusion-positive cancers other than thyroid and lung cancer

byJohan PushaniandSze Wah Samuel Chan
October 5, 2022
in Chronic Disease, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Objective response rate was 43.9%. Patients treated with selpercatinib also experienced improved overall response and time on treatment than their previous respective therapies.

2. Most common adverse events of grades 3 or higher were hypertension, increased alanine aminotransferase and increased aspartate aminotransferase.

Evidence Rating Level: 2 (Good)

Study Rundown: Recently, there have been genome-driven oncology therapies that showed clinical benefit in the setting of specific biomarkers, regardless of the cancer type. Selpercatinib (a selective RET kinase inhibitor) has previously shown efficacy in RET fusion-positive thyroid and lung cancers. This study explored the efficacy and safety of selpercatinib in all other RET-positive cancer types and this is the 1st interim analysis. Tumour-agnostic patients with RET fusion-positive cancer were chosen, all of whom had disease progression after previous systemic therapies or had no satisfactory therapeutic options. Objective response rate (ORR), per independent review committee and investigator assessment, was 43.9% for both. At the time of the interim analysis, progression-free survival (PFS) and duration of response both had clinically meaningful improvements. The safety profile of selpercatinib was consistent with previous reports. The most common treatment-emergent adverse events (TEAEs) of grades 3 or higher were hypertension, increased alanine aminotransferase and increased aspartate aminotransferase. The strength of this interim study is that it highlights a potential therapeutic agent for tumour-agnostic populations, which currently only have 2 approved treatment options. Limitations to this interim study include a short follow-up, a small sample size, a non-randomized patient population, and no comparison group. Overall, selpercatinib is a promising treatment option for tumour-agnostic populations with RET fusion-positive tumours.

Click to read the study in The Lancet Oncology

Relevant Reading: Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes

RELATED REPORTS

#VisualAbstract: Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer

#VisualAbstract: First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive Non-Small Cell Lung Cancer

Selpercatinib vs Chemotherapy and Pembrolizumab in RET Positive NSCLC

In-Depth [prospective cohort]: This international phase 1/2 basket trial included 41 tumour-agnostic patients with RET fusion-positive cancers other than thyroid or lung cancers. These patients all had disease progression after previous systemic therapies or had no satisfactory therapeutic options. ORR, both by independent review committee and investigator assessment was 43.9% (95% confidence interval [CI], 28.5 to 60.3; 18 of 41 patients). From an exploratory ad-hoc intra-patient analysis of best overall response, responses to selpercatinib were seen in 46% of patients who previously received systemic therapy. Median PFS by independent review committee was 13.2 months (95% CI, 7.4 to 26.2) and 11.1 months (95% CI, 5.6 to 19.1) as per investigator assessment. Median duration of response was 24.5 months (95% CI, 9.2 to not evaluable) and 18.4 months (95% CI, 9.2 to not evaluable), respectively. The most common TEAEs of grades 3 or higher were hypertension (22% of patients), increased alanine aminotransferase (16%) and increased aspartate aminotransferase (13%). Overall, in this interim analysis, selpercatinib showed clinically meaningful activity in a tumour-agnostic cohort with RET fusion-positive tumours.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: RET-fusionselpercatinibtumour-agnostic
Previous Post

Selpercatinib continues to demonstrate effective response in RET fusion-positive NSCLC

Next Post

Glargine and liraglutide are effective glucose-lowering medications in type 2 diabetes

RelatedReports

#VisualAbstract: Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis
StudyGraphics

#VisualAbstract: Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer

November 24, 2023
#VisualAbstract: First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive Non-Small Cell Lung Cancer
StudyGraphics

#VisualAbstract: First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive Non-Small Cell Lung Cancer

November 22, 2023
Pulmonary MRI with ultrashort echo time is comparable to pulmonary CT
Oncology

Selpercatinib vs Chemotherapy and Pembrolizumab in RET Positive NSCLC

November 7, 2023
Oophorectomy associated with reduced cancer risk and all-cause mortality for BRCA1/2 patients
Oncology

Selpercatinib continues to demonstrate effective response in RET fusion-positive NSCLC

September 26, 2022
Next Post
Insulin costs rose exponentially, regardless of formulation or patent

Glargine and liraglutide are effective glucose-lowering medications in type 2 diabetes

More permissive parameters for active surveillance eligibility is potentially possible in slow-growing thyroid cancers

Unpaid caregivers of older adults experience emotional, physical, and financial difficulty

Increased pre-chemotherapy inflammatory biomarkers (IL-6 and CRP) correlated to increased risk of frailty post-chemotherapy in older breast cancer patients

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Time-restricted eating does not confer changes in sleep, mood, or quality of life
  • Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
  • Ablation may reduce stroke risk, death, heart failure hospitalization in patients with atrial fibrillation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.